Trial Profile
Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jun 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Buparlisib (Primary)
- Indications Colorectal cancer; Glioblastoma; Lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors SCRI Development Innovations
- 08 Jun 2020 Status changed from active, no longer recruiting to completed.
- 28 May 2019 Planned End Date changed from 1 Feb 2018 to 29 Feb 2020.
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.